Literature DB >> 21091015

Pharmacologic vitreolysis.

Marc-André Rhéaume1, Demetrios Vavvas.   

Abstract

It is now well recognized that vitreous plays an important role in the pathogenesis of various retinal disorders. In many instances it can be addressed with pars plana vitrectomy, although this approach, like any surgery, has its limitations. The search for alternatives or adjunct to surgery has led to the development of pharmacologic vitreolysis. The use of intravitreal agents to alter the vitreous in order to reduce or eliminate its role in disease seems promising. The purpose of this article is to summarize the present knowledge on pharmacologic vitreolysis. A review of the different agents used and of ongoing trials will be presented. Also, current understanding of vitreous structure and its interaction with the retina will be discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21091015     DOI: 10.3109/08820538.2010.518865

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  4 in total

Review 1.  Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma.

Authors:  Kang Zhang; Liangfang Zhang; Robert N Weinreb
Journal:  Nat Rev Drug Discov       Date:  2012-06-15       Impact factor: 84.694

2.  Ocriplasmin for treatment of stage 2 macular holes: early clinical results.

Authors:  John B Miller; Leo A Kim; David M Wu; Demetrios G Vavvas; Dean Eliott; Deeba Husain
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2014 Jul-Aug       Impact factor: 1.300

3.  Rhegmatogenous retinal detachment following intravitreal ocriplasmin.

Authors:  Haifa A Madi; Richard J Haynes; Diana Depla; Morten D de la Cour; Sarit Lesnik-Oberstein; Mahi M K Muqit; Niall Patton; Nick Price; David H W Steel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-08       Impact factor: 3.117

4.  Retinal breaks due to intravitreal ocriplasmin.

Authors:  Ruwan A Silva; Darius M Moshfeghi; Theodore Leng
Journal:  Clin Ophthalmol       Date:  2014-08-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.